Financial News

Date Title and Summary Additional Formats
Toggle Summary Michigan Community Hospital Begins Patient Treatments with ViewRay's MRIdian Linac
Sparrow Health System Now Delivering On-Table Adaptive Therapy with New MRI-Guided Radiation Therapy System CLEVELAND , Dec. 19, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Sparrow Health System in Lansing, Michigan has begun patient treatments with MRIdian® Linac, a
Toggle Summary First MRIdian MRI-Guided Radiotherapy Treatments Begin in the United Kingdom
GenesisCare Oxford Brings the Benefits of Continuous Soft-Tissue Imaging and Adaptive Treatment Delivery to UK Cancer Patients CLEVELAND , Dec. 17, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the first MRIdian MRI-guided radiotherapy system in the United Kingdom ( UK ) –
Toggle Summary ViewRay Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
CLEVELAND , Dec. 6, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the completion of its previously announced underwritten public offering of
Toggle Summary ViewRay Announces Pricing of Public Offering of Common Stock
CLEVELAND , Dec. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 41,550,000 shares of common stock
Toggle Summary ViewRay Announces Proposed Public Offering of Common Stock
CLEVELAND , Dec. 2, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $75.0 million of shares of
Toggle Summary ViewRay Announces Collaborations with Elekta and Medtronic
CLEVELAND , Dec. 2, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) (" Elekta ") to advance the knowledge and use of MR-guided radiation therapy.
Toggle Summary ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
CLEVELAND , Nov. 20, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the 2019 Piper Jaffray 31 st Annual Healthcare Conference in New York, New York . Scott Drake , President and CEO, will give a presentation at 1:30p.m.
Toggle Summary ViewRay Reports Third Quarter 2019 Results
CLEVELAND , Nov. 12, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the third quarter ended September 30, 2019. Third Quarter 2019 Summary: Total revenue was $20.9 million in the quarter, primarily from three revenue units, compared to $17.7 million ,
Toggle Summary European Symposium to Advance Adoption of MRI-Guided Radiation Therapy
Educational Event to Feature Presentations from MRIdian® Users and ESTRO Past President on the Strategic, Economic, Clinical and Technical Aspects of MRI-Guided Radiation Therapy CLEVELAND , Oct. 24, 2019 /PRNewswire/ -- Clinicians interested in learning more about MRI-guided radiation therapy can
Toggle Summary ViewRay Announces Preliminary Third Quarter 2019 Results and Details of Upcoming Conference Call
CLEVELAND , Oct. 15, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019. The preliminary results have not been audited and are subject to change. Selected Third Quarter Preliminary Results: Total revenue of $20.9 million in the third
Toggle Summary Patient Treatments with ViewRay's MRIdian Linac Begin in New England
Joint Cancer Program in Boston First in New England to Offer MRI-Guided Radiation Therapy     CLEVELAND , Oct. 7, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian® Linac System at Dana-Farber/Brigham
Toggle Summary Penn State Health Enters into Master Purchase Agreement with ViewRay for MRIdian® Systems
Immediate order of one system with ability to purchase an additional three systems CLEVELAND , Sept. 16, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Penn State Health has entered into a master agreement for the purchase of up to four MRIdian systems, placing an order for
Toggle Summary ViewRay Announces Collaboration with Stanford Health Care
Stanford Health Care to Acquire a ViewRay MRIdian System CLEVELAND , Sept. 12, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Stanford Health Care in Stanford, California , will acquire a MRIdian, the world's leading MR-guided radiation therapy system.
Toggle Summary Leading Radiation Oncology Meeting to Feature Unique Capabilities and Compelling Patient Outcomes with ViewRay's MRIdian
Clinicians from 17 Hospitals Worldwide to Present Clinical Experience with MRIdian MRI-Guided Radiation Therapy at ASTRO CLEVELAND , Sept. 10, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® and MRIdian Linac MRI-guided radiation therapy systems will
Toggle Summary ViewRay to Host Investor Meeting at 2019 ASTRO Annual Meeting in Chicago
CLEVELAND , Aug. 27, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced that the Company will host a physician-led informational discussion for investors and analysts during the 2019 American Society of Radiation Oncology (ASTRO) Annual Meeting in Chicago .
Toggle Summary ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers
Study Shows Low Incidence of Early Toxicity Using Stereotactic Body Radiation Therapy (SBRT) While Eliminating Potential Complications and Costs Associated with Implanted Markers CLEVELAND , Aug. 19, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today the acceptance of publication by
Toggle Summary ViewRay® to Participate in Upcoming Investor Conferences
CLEVELAND , Aug. 15, 2019 /PRNewswire/ --  ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY . Event :          Baird 2019 Global Healthcare Conference Format:           Fireside Chat & 1x1 Meetings Date
Toggle Summary ViewRay Reports Second Quarter 2019 Results
CLEVELAND , Aug. 8, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2019 . Second Quarter 2019 Summary: The Company is updating 2019 guidance and now anticipates total revenue in the range of $80 million to $95 million , and
Toggle Summary ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019
CLEVELAND , July 18, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2019 financial results. ViewRay will hold a conference call to discuss results on Thursday, August 8, 2019 at 4:30 p.m. ET / 1:30 p.m. PT .
Toggle Summary ViewRay Announces Appointment of Dr. Gail Wilensky to its Board of Directors
CLEVELAND , July 16, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Dr. Gail Wilensky to its Board of Directors, effective today. Dr. Wilensky has an extensive track record in healthcare as a policy leader, reimbursement expert, and board member.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select